Harbor Investment Advisory LLC Has $30,000 Position in Palantir Technologies Inc. (NYSE:PLTR)

Harbor Investment Advisory LLC cut its stake in shares of Palantir Technologies Inc. (NYSE:PLTR – Get Rating) by 80.6% during the 2nd quarter, Holdings Channel reports. The fund owned 3,300 shares of the company’s stock after selling 13,750 shares during the period. Harbor Investment Advisory LLC’s holdings in Palantir Technologies were worth $30,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. IndexIQ Advisors LLC bought a new position in shares of Palantir Technologies during the 1st quarter worth $27,000. Endurance Wealth Management Inc. bought a new position in Palantir Technologies during the first quarter worth about $27,000. Herold Advisors Inc. purchased a new position in shares of Palantir Technologies in the first quarter worth about $35,000. TCI Wealth Advisors Inc. raised its position in shares of Palantir Technologies by 58.5% in the first quarter. TCI Wealth Advisors Inc. now owns 2,820 shares of the company’s stock valued at $39,000 after purchasing an additional 1,041 shares during the period. Finally, UMB Bank NA MO lifted its stake in shares of Palantir Technologies by 58.6% during the 1st quarter. UMB Bank NA MO now owns 3,240 shares of

Pressure Technologies (LON:PRES) Shares Cross Below 50 Day Moving Average of $71.60

Pressure Technologies plc (LON:PRES – Get Rating)’s stock price crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of GBX 71.60 ($0.87) and traded as low as GBX 65 ($0.79). Pressure Technologies shares last traded at GBX 66.50 ($0.80), with a volume of 9,635 shares traded.

Pressure Technologies Stock Down 1.5%

The stock has a 50-day moving average of GBX 71.60 and a two-hundred day moving average of GBX 79.34. The company has a market cap of £20.66 million and a P/E ratio of -5.54. The company has a debt-to-equity ratio of 44.16, a quick ratio of 1.24 and a current ratio of 1.73.

Pressure Technologies Company Profile

(Get Rating)

Pressure Technologies plc, through its subsidiaries, designs and manufactures high pressure components and systems for the oil and gas, defense, industrial gases, and hydrogen energy markets in the United Kingdom, Europe, and internationally. It operates through two segments, Cylinders and Precision Machined Components.

Read More

Receive News & Ratings for Pressure Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pressure Technologies and related companies with

Pressure Technologies (LON:PRES) Stock Crosses Below Fifty Day Moving Average of $71.21

Pressure Technologies plc (LON:PRES – Get Rating)’s share price crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of GBX 71.21 ($0.86) and traded as low as GBX 69.98 ($0.85). Pressure Technologies shares last traded at GBX 70 ($0.85), with a volume of 4,314 shares trading hands.

Pressure Technologies Stock Performance

The company has a debt-to-equity ratio of 44.16, a current ratio of 1.73 and a quick ratio of 1.24. The firm has a market cap of £21.75 million and a price-to-earnings ratio of -5.83. The company has a fifty day moving average price of GBX 71.21 and a two-hundred day moving average price of GBX 79.33.

Pressure Technologies Company Profile

(Get Rating)

Pressure Technologies plc, through its subsidiaries, designs and manufactures high pressure components and systems for the oil and gas, defense, industrial gases, and hydrogen energy markets in the United Kingdom, Europe, and internationally. It operates through two segments, Cylinders and Precision Machined Components.

See Also

Receive News & Ratings for Pressure Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pressure Technologies and

Kape Technologies (LON:KAPE) Hits New 52-Week Low at $255.00

Kape Technologies PLC (LON:KAPE – Get Rating)’s share price reached a new 52-week low during trading on Thursday . The stock traded as low as GBX 255 ($3.08) and last traded at GBX 256 ($3.09), with a volume of 257194 shares changing hands. The stock had previously closed at GBX 261 ($3.15).

Wall Street Analysts Forecast Growth

Separately, Shore Capital reaffirmed a “house stock” rating and issued a GBX 750 ($9.06) price target on shares of Kape Technologies in a report on Tuesday, July 19th.

Kape Technologies Stock Performance

The company has a current ratio of 0.26, a quick ratio of 0.16 and a debt-to-equity ratio of 16.26. The firm has a fifty day simple moving average of GBX 286.32 and a 200 day simple moving average of GBX 330.18. The stock has a market cap of £900.59 million and a price-to-earnings ratio of 3,200.00.

Kape Technologies Company Profile

Want More Great Investing Ideas?

(Get Rating)

Kape Technologies PLC, together with its subsidiaries, develops and distributes digital products in the online security space. It operates through Digital Security, Digital Content, and Digital Privacy segments. The company offers CyberGhost, ZenMate, Express, and private internet access that provides cybersecurity SaaS with a

Oppenheimer & Co. Inc. Takes $412,000 Position in SPX Technologies, Inc. (NYSE:SPXC)

Oppenheimer & Co. Inc. acquired a new stake in shares of SPX Technologies, Inc. (NYSE:SPXC – Get Rating) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 8,352 shares of the company’s stock, valued at approximately $412,000.

Several other large investors also recently made changes to their positions in the business. State Street Corp boosted its position in shares of SPX Technologies by 2.8% during the 4th quarter. State Street Corp now owns 1,547,751 shares of the company’s stock valued at $92,370,000 after purchasing an additional 42,505 shares in the last quarter. Segall Bryant & Hamill LLC boosted its position in shares of SPX Technologies by 2.2% during the 4th quarter. Segall Bryant & Hamill LLC now owns 1,159,306 shares of the company’s stock valued at $69,190,000 after purchasing an additional 25,353 shares in the last quarter. GW&K Investment Management LLC boosted its position in shares of SPX Technologies by 18.3% during the 1st quarter. GW&K Investment Management LLC now owns 923,283 shares of the company’s stock valued at $45,620,000 after purchasing an additional 142,785 shares in the last quarter. Geode Capital Management LLC boosted its

Dynavax Technologies (NASDAQ:DVAX) Cut to C+ at TheStreet

TheStreet cut shares of Dynavax Technologies (NASDAQ:DVAX – Get Rating) from a b- rating to a c+ rating in a report released on Thursday morning, TheStreetRatingsTable reports.

Separately, StockNews.com upgraded Dynavax Technologies from a hold rating to a buy rating in a report on Friday, August 5th. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $28.00.

Dynavax Technologies Stock Performance

Dynavax Technologies stock opened at $11.21 on Thursday. The stock’s 50-day moving average is $13.86 and its 200-day moving average is $11.89. The company has a market cap of $1.42 billion, a price-to-earnings ratio of 8.01 and a beta of 1.30. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.77 and a quick ratio of 2.55. Dynavax Technologies has a 12 month low of $7.26 and a 12 month high of $21.39.

Insider Activity at Dynavax Technologies

Want More Great Investing Ideas?

In related news, SVP Robert Janssen sold 7,938 shares of the firm’s stock in a transaction dated Tuesday, August 9th.

Qube Research & Technologies Ltd Sells 17,083 Shares of BioAtla, Inc. (NASDAQ:BCAB)

Qube Research & Technologies Ltd decreased its position in shares of BioAtla, Inc. (NASDAQ:BCAB – Get Rating) by 48.8% in the 1st quarter, Holdings Channel reports. The fund owned 17,936 shares of the company’s stock after selling 17,083 shares during the quarter. Qube Research & Technologies Ltd’s holdings in BioAtla were worth $90,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Los Angeles Capital Management LLC bought a new position in shares of BioAtla during the 1st quarter worth $333,000. Woodline Partners LP grew its stake in shares of BioAtla by 196.1% during the 4th quarter. Woodline Partners LP now owns 446,141 shares of the company’s stock worth $8,758,000 after acquiring an additional 295.446 shares during the period. Russell Investments Group Ltd. bought a new position in shares of BioAtla during the 1st quarter worth $286,000. SG Americas Securities LLC grew its stake in shares of BioAtla by 165.0% during the 1st quarter. SG Americas Securities LLC now owns 13,524 shares of the company’s stock worth $68,000 after acquiring an additional 8,421 shares during the period. Finally, Nisa Investment Advisors LLC purchased a

Qube Research & Technologies Ltd Reduces Stock Position in Cactus, Inc. (NYSE:WHD)

Qube Research & Technologies Ltd cut its stake in Cactus, Inc. (NYSE:WHD – Get Rating) by 83.0% in the first quarter, HoldingsChannel reports. The institutional investor owned 3,680 shares of the company’s stock after selling 18,017 shares during the quarter. Qube Research & Technologies Ltd’s holdings in Cactus were worth $209,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. UMB Bank NA MO acquired a new stake in shares of Cactus in the fourth quarter valued at approximately $31,000. Private Capital Group LLC grew its position in shares of Cactus by 28.4% in the first quarter. Private Capital Group LLC now owns 1,650 shares of the company’s stock valued at $94,000 after purchasing an additional 365 shares during the last quarter. Chilton Capital Management LLC acquired a new stake in shares of Cactus in the fourth quarter valued at approximately $170,000. Park Avenue Securities LLC acquired a new stake in shares of Cactus in the first quarter valued at approximately $208,000. Finally, Stephens Inc. AR grew its position in shares of Cactus by 2.7% in the fourth quarter. Stephens Inc. AR now owns 7,669

SolarEdge Applied sciences, Inc. (NASDAQ:SEDG) Receives Consensus Advice of “Reasonable Purchase” from Analysts

Shares of SolarEdge Applied sciences, Inc. (NASDAQ:SEDG – Get Ranking) have earned a consensus suggestion of “Maintain” from the twenty-eight brokerages which can be at present masking the inventory, Marketbeat studies. Two analysts have rated the inventory with a promote suggestion, seven have issued a maintain suggestion and twelve have given a purchase suggestion to the corporate. The common twelve-month worth goal amongst analysts which have issued scores on the inventory within the final 12 months is $358.24.

SEDG has been the subject of plenty of latest analyst studies. Guggenheim upped their goal worth on SolarEdge Applied sciences from $348.00 to $389.00 in a analysis report on Wednesday, August third. JPMorgan Chase & Co. lifted their worth goal on shares of SolarEdge Applied sciences from $373.00 to $419.00 and gave the corporate an “obese” ranking in a analysis report on Monday, August eighth. TheStreet upgraded shares of SolarEdge Applied sciences from a “c” ranking to a “b-” ranking in a analysis report on Tuesday, August 2nd. Citigroup boosted their worth goal on shares of SolarEdge Applied sciences from $255.00 to $300.00 and gave the inventory a “maintain” ranking in a analysis report on Tuesday, Could third. Lastly, Morgan Stanley lowered

Three docs from Ontario hospital community die inside one week

A hospital community in Ontario is mourning the lack of three docs who died inside days of each other final week.

“It’s with deep unhappiness that Trillium Well being Companions mourns the lack of three of our physicians who just lately handed away,” Trillium Well being spokesperson Amit Shilton advised CTV Information Toronto in a press release on Wednesday.

“Dr. Jakub Sawicki, Dr. Stephen McKenzie and Dr. Lorne Segall have been trusted colleagues who have been dedicated to caring for his or her sufferers and group.”

Trillium Well being, which operates hospitals in Toronto and Mississauga, stated rumors circulating on social media that the deaths have been associated to the COVID-19 vaccine are false.

“The rumors circulating on social media is just not true. Their passings weren’t associated to the COVID-19 vaccine,” Shilton stated.

On July 17, Dr. Lorne Segall, a 49-year-old otolaryngologist at Credit score Valley Hospital, handed away after a “ridiculously unfair and exhausting fought year-long battle with superior lung most cancers,” his obituary reads.

He was an “adored” husband of twenty-two years and the “devoted” father of a 16, 14 and 9 yr outdated.

“He shared many pursuits along with his youngsters together with an arcane degree